Collectively, gene expression results suggest an important role for TIM-3, but not VISTA and Galectin-9, in B-ALL and it seems that TIM-3 could be a candidate for immune checkpoint therapy. Here, VSIR is linked to precursor B-cell acute lymphoblastic leukemia.